tbuckley/cabot-search huggingface dataset:
Neural Tube Defect Cluster Stresses Importance of Folic Acid Supplements
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mechanism of biologic therapy for pre B-cell acute lymphoblastic leukemia with CRLF2 overexpression.
Authors: WayAnne Watson, Cornelia Stoian, Jacqueline S. Coats, Hossam AlKashgari, Veriah Vidales, Ineavely Baez, Juliette Personius, Hannah Choi, Benjamin Becerra, Rishikesh Chavan, Muhammad Omair Kamal, Shadi Farzin Gohar, Kimberly J Payne
Journal: Journal of Clinical Oncology (2019)

7035 Background: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, of which pre B-cell ALL with CRLF2 overexpression is a high risk subtype. CRLF2 B-ALL is associated with poor outcome, increased rate of relapse, and health disparities in Hispanic children. Together with IL-7 receptor alpha (IL-7Rα), CRLF2 makes up a receptor complex that is activated by the cytokine, thymic stromal lymphopoetin (TSLP). Activation of the receptor complex leads to JAK2/STAT5 and PI3/AKT/mTOR signals that promote leukemia cell survival and proliferation. To study the role of TSLP in CRLF2 B-ALL, we developed a patient-derived xenograft (PDX) model of CRLF2 B-ALL that allows us to alter circulating levels of human TSLP (hTSLP). We generated PDX from CRLF2 B-ALL cells harvested from patient samples and compared leukemia burden in mice with varying levels of hTSLP. In PDX models with hTSLP levels at or below physiological levels in pediatric cancer patients, CRLF2 B-ALL cells grew robustly. However, in PDX with elevated levels of hTSLP, leukemia cells were essentially eliminated. Our objective is to elaborate on the mechanism of high dose hTSLP’s antileukemic effect. Methods: We performed TSLP dose response studies and used flow cytometry to evaluate the effect of TSLP on SOCS protein expression, CRLF2 signaling shutdown, and loss of TSLP receptor components. Results: CRLF2 B-ALL cells cultured with hTSLP showed a dose-dependent loss in the ability to induce STAT5 and S6 phosphorylation following hTSLP stimulation. This loss was correlated with the loss of IL-7Rα, and maintained for 24-48 hours following a pulse of high-dose, but not low-dose, hTSLP. The loss of signaling and surface IL-7Rα could be prolonged if high-dose hTSLP levels were maintained. Flow cytometry analysis showed that high-dose hTSLP upregulated SOCS1 and SOCS3 proteins in CRLF2 B-ALL cells. Whole genome microarray showed that SOCS1, SOCS2, SOCS3 and CISH mRNA were upregulated in primary CRLF2 B-ALL cells cultured with high dose hTSLP. Conclusions: These data support the hypothesis that TSLP exerts its anti-leukemia effects through shutdown of CRLF2-mediated signals and that these effects are at least partially mediated by the loss of the IL-7Rα component, and potentially through SOCS family proteins. These studies elucidate the mechanism of the human TSLP cytokine as a potential biologic therapy to treat CRLF2 B-ALL. Supported in part by 1R01CA209829 (KJP), 1R43CA224723 (KJP), ASH HONORS Award 2018-2019 (WBW), and Alpha Omega Alpha Carolyn L. Kuckein Student Research Fellowship 2018-2019 (WBW).
Insomnia
Authors: Philip Solomon
Journal: New England Journal of Medicine (1956)

INSOMNIA is one of the commonest symptoms encountered by the physician, occurring frequently in patients in all branches of medicine; indeed, it has been experienced at one time or another by practically everyone, sick or well. In this country more than $100,000,000 is spent annually on soporifics. Medical textbooks contain few references to insomnia, and medical students are often given little understanding of the condition.Insomnia may be defined as the inability either to fall asleep or to maintain sleep adequately. Before its causes and treatment are discussed it may be well to consider what is known clinically about sleep . . .
Miscellanea Medica
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Meetings in the United States
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE VETO OF THE ANTI-CORONER'S BILL IN NEW YORK
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE SPECIAL FUND: TRADE UNION OR TRUST?
Authors: E. R. Fothergill
Journal: BMJ (1914)

Two facts are undisputed-fiust, Dublin lhas, of cities in the United Kingdom, the greatest-number of siigle and louble-room tenements in proportion to its population, and the greatest overcrowding of these tenements; and, secondly, tlle higlhest death-rate.M tiuch.muust be elimi- niated from the Registrar-General's returns before it is possible to-obtain the real death-rate of the slum areas.The Dublin i'egistr-ation area includes sh places as the southern suburbs, wlhe-e probably-one of the lowest death- rates in the United Kingdom prevails.The Dublin deatlh- rate wo'ildd be mtchli higiher if the city alone were segre- gated.Next to Dublin -in its higlh percentage of tene- inents is Finsbury, where, in 1906, Dr. Newman made an official return, showing that the average deaths in onn- and two-roomed tenements were -abotit 33 per 1,000 annually, while its tllree-roomued dwellings slhow a deatlh- rate of 14.8.In view of what the Dopartmeutal Commrissioners said about the sanitation and cleanliness of the Dublin tenements, ib. is not too much to assume that the death-rate in the.lDublin, slums is at least equal to that. in Finsbury.Forty-two per cent.(130,000) of tle inhabitants of Dublin.live~in tenements of one and twa roomis, and, applying the Fiusbury average of 33 per 1,000, it would appear that 4,200 -of these slum.dwellers die every year.If the rate were reduced to the Finsbury average of 14.8 for,three-xoom, dwellings, nearly 2,500 lives would be saved annually.Many. of these 130,000 peoplelive in dwellings which are registered by the Corporation as being " unfit for human habitation."DERRY WATER SCHEME.
PLoS Medicine Issue Image | Vol. 7(12) December 2010
Journal: PLoS Medicine (2010)

The risk of tuberculosis (TB) and latent TB is much higher in prison populations than in the general population. Specifically, the average incidence of TB in prisons was found to be 23 times higher than that of the general population, and 26 times higher for latent TB, in a systematic review by Iacopo Baussano (Imperial College, London) and colleagues, published in the December issue of PLoS Medicine. In the review, the authors used findings from published studies and data from the WHO to show that the spread of TB and latent TB within prisons can substantially increase their incidence in the general population. The researchers went on to suggest that improvements in prison TB control would not only help to protect prisoners and staff from within-prison spread of TB, but could also help to reduce national TB burdens. In an accompanying editorial, the PLoS Medicine Editors discuss the persistent problem of tuberculosis in prisons around the world and how it affects the health of inmates and the community outside, concluding, "The new systematic review published in PLoS Medicine provides much-needed evidence for policymakers, including the WHO, to renew their efforts to tackle TB in prisons...the publication of this systematic review marks a shift from considering the incidence of TB in each prison population to considering the massive global impact of tuberculosis in prisons." Image Credit: Alexander Lütjen
PANCREATIC LIPASE IN ACUTE PANCREATITIS
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Authors: Louise K Mercer, James B Galloway, Mark Lunt, Rebecca Davies, Audrey L S Low, William G Dixon, Kath D Watson, Deborah P M Symmons, Kimme L Hyrich
Journal: Annals of the Rheumatic Diseases (2016)

Patients with rheumatoid arthritis (RA) are at increased risk of lymphoma compared with the general population. There are concerns that tumour necrosis factor inhibitors (TNFi) may exacerbate this risk. However, since the excess risk of lymphoma in RA is related to the cumulative burden of inflammation, TNFi may conversely reduce the risk of lymphoma by decreasing the burden of inflammation. The aim of this study was to compare the risk of lymphoma in subjects with RA treated with TNFi with those treated with non-biological therapy.Subjects diagnosed by a rheumatologist with RA enrolled in the British Society for Rheumatology Rheumatoid Arthritis Register (BSRBR-RA), a prospective cohort study, were followed until first lymphoma, death or until 30 November 2013. Rates of lymphoma in the TNFi and non-biological-treated cohorts were compared using Cox regression.11 931 TNFi-treated patients were compared with 3367 biological-naive patients. 84 lymphomas (88 (95% CI 70 to 109) per 100 000 person-years) were reported in the TNFi cohort and 30 lymphomas (154 (95% CI 104 to 220)) in the biological-naive cohort. After adjusting for differences in baseline characteristics, there was no difference in the risk of lymphoma for the TNFi versus the biological-naive group: HR 1.00 (95% CI 0.56 to 1.80). No risk differences were observed for individual TNFi.In medium-term follow-up, there is no evidence that tumour necrosis factor inhibition influences the risk of lymphoma over the background risk in subjects with RA.
Effects of Left Ventricular Receptor Stimulation on Coronary Blood Flow in Conscious Dogs
Authors: Irving H. Zucker, Kurtis G. Cornish, Johnnie Hackley, Kay Bliss
Journal: Circulation Research (1987)

The present study was undertaken to determine the effects of intracoronary administration of the veratrum alkaloid veratridine on coronary blood flow and resistance in conscious, chronically instrumented intact and sinoaortic denervated dogs.Ten dogs were instrumented with a Doppler flow probe on the left anterior descending coronary artery.A chronic catheter was placed in the left circumflex coronary artery and in the aorta and left atrium.A Konigsberg pressure cell was placed in the left ventricle, and pacing leads were attached to the left atrium and ventricle.While heart rate was kept constant, bolus intracoronary injections of veratridine (0.1-0.4 /xg/kg) were administered in the unblocked state after /3,-receptor blockade, after a-receptor blockade, and after cholinergic blockade.In the unblocked state, late diastolic coronary resistance fell by 34.7±5.0%.The maximum response was achieved at a time when arterial pressure was not significantly different from control.After /3r blockade, coronary resistance fell by 29.1 ±7.9%.After combined a-and /3-blockade, coronary resistance fell by 25.4 ± 6.5% in response to veratridine.The addition of atropine completely blocked the decrease in coronary resistance, changing it by an average of -0.10 ±2.5%.The responses in sinoaortic denervated dogs were similar to those in intact animals.The response was abolished by vagotomy.We conclude that cardiac receptor stimulation causes a reflex decrease in coronary resistance in the awake dog that is completely accountable by a cholinergic mechanism.
JAMA Reference Directories
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Heart Disease in World Leaders
Journal: Annals of Internal Medicine (2001)

Summaries for Patients20 February 2001Heart Disease in World LeadersSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-4-200102200-00007 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Coronary heart disease (CHD) is a condition in which the arteries that supply blood to the heart become narrowed. When not enough blood gets to the heart, a type of chest pain called angina occurs. If the flow of blood to a section of the heart becomes blocked completely, that portion of the heart muscle dies, a condition known as myocardial infarction or “heart attack.” Coronary heart disease can also lead to abnormal heart rhythms. It is a frequent cause of death among world political leaders.Why did ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Impact of Coronary Heart Disease on World Leaders.” It is in the 20 February 2001 issue of Annals of Internal Medicine(volume 134, pages 287-290). The authors are AM Girardi, LR Pyenson, J Morris, and FX Brickfield.Summaries for Patientsare a service provided by Annalsto help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. Previousarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoImpact of Coronary Heart Disease on World Leaders Alyce M. Girardi , Leslie R. Pyenson , Jon Morris , and Francis X. Brickfield Metrics 20 February 2001Volume 134, Issue 4Page: I-82KeywordsAnginaArteriesBloodCongenital heart diseaseCoronary heart diseaseDrug therapyMyocardial infarctionMyocardiumPopulation statisticsSurgery ePublished: 20 February 2001 Issue Published: 20 February 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Pheochromocytoma followed up for 21 years without therapy
Authors: R. B. Stein
Journal: JAMA (1971)

Pheochromocytoma and the symptoms produced by excessive catecholamine secretion can usually be cured with surgical excision of the tumor. Very little information is available in the literature regarding the prognosis of medically managed or untreated cases of pheochromocytoma because such tumors are usually surgically removed promptly after the diagnosis is established. A patient with pheochromocytoma, described in this report, refused surgery and was followed up for 21 years without significant treatment until death occurred during a hypertensive crisis.
Aluminum Intoxication
Authors: Allen C. Alfrey
Journal: New England Journal of Medicine (1984)

With the advent of long-term hemodialysis therapy it was anticipated that the symptoms of uremia would be modified and new diseases might occur simply as a result of prolonging a modified uremic state by artificial means. The first new disease discovered in patients with uremia undergoing dialysis was a heretofore undescribed neurologic syndrome called dialysis encephalopathy.1 Subsequently, in 1976, the finding of high concentrations of aluminum in the gray matter of the brains of patients dying from this disease led to the suggestion that it resulted from aluminum intoxication.2 Two years later, European investigators first noted the association between dialysis . . .
Abstracts
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal